Charles Fuchs, MD: Experience With Patients on Bevacizumab Plus Chemotherapy
What is your experience with patients who receive bevacizumab plus a CT regimen? What types of issues/side effects do they report with treatment?
As I say, the combination of any chemotherapy with bevacizumab is really well-tolerated, and the side effects that we'll see have been principally limited to the side effects that we experience with the chemotherapy. That is, bevacizumab doesn't really contribute to side effects. If a side effect occurs, it's going to be in the form of hypertension, which will arise a few months after starting and if that were the case, I wouldn't necessarily change the regimen, but I would certainly provide treatment like an ACE inhibitor for the hypertension, which is usually quite effective.
We do check urine proteins periodically for patients on chemotherapy plus bevacizumab, and were there to be significant elevations in proteinuria, that might be a circumstance to discontinue or suspend the use of bevacizumab. Frankly, even there that's so uncommon that I can't even remember the last time I had to do that.
Unresectable Colon Cancer: Case 1
68-year-old man was diagnosed with advanced, unresectable colon cancer has just started treatment with FOLFIRI plus bevacizumab.
Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC
April 16th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Study Finds Susceptibility Gene Variations by Race/Ethnicity in Early-Onset CRC
February 20th 2024In an interview with Targeted Oncology, Andreana N. Holowatyj, PhD, MSCI, discussed data from a study which found racial and ethnic differences in susceptibility genes for early-onset colorectal cancer, suggesting current multigene panel tests may not be accurate for diverse populations.
Read More
